Enliven Therapeutics, Inc. (ELVN)
45.09
-0.08
(-0.18%)
USD |
NASDAQ |
Sep 25, 09:55
Enliven Therapeutics Research and Development Expense (Quarterly) : 28.99M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 28.99M |
| March 31, 2026 | 20.67M |
| December 31, 2025 | 21.20M |
| September 30, 2025 | 18.16M |
| June 30, 2025 | 21.41M |
| March 31, 2025 | 24.82M |
| December 31, 2024 | 20.64M |
| September 30, 2024 | 21.18M |
| June 30, 2024 | 18.75M |
| March 31, 2024 | 19.89M |
| December 31, 2023 | 17.83M |
| September 30, 2023 | 19.53M |
| June 30, 2023 | 15.11M |
| March 31, 2023 | 11.81M |
| Date | Value |
|---|---|
| December 31, 2022 | 0.18M |
| September 30, 2022 | 7.769M |
| June 30, 2022 | 7.885M |
| March 31, 2022 | 7.02M |
| December 31, 2021 | 10.86M |
| September 30, 2021 | 10.40M |
| June 30, 2021 | 10.07M |
| March 31, 2021 | 7.115M |
| December 31, 2020 | 8.959M |
| September 30, 2020 | 9.533M |
| June 30, 2020 | 7.869M |
| March 31, 2020 | 5.793M |
| December 31, 2019 | 5.942M |
| September 30, 2019 | 5.141M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Definium Therapeutics, Inc. | 48.66M |
| Cocrystal Pharma, Inc. | 2.142M |
| CNBX Pharmaceuticals, Inc. | -- |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 52.30M |